entertainment -WSS

entertainment

author：explore 2025-08-25 05:57:09 - browse：6328

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： SAMSHA loosens regulations on methadone treatment centers

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

Do digital therapeutics have a future in medicine?

Even great ERs can’t make up for American health disparities

Juul spent big to court Black leaders to promote its e

White House drug shortage group privately met with industry

Gilgo Beach: Police identify another victim in serial killing investigation

entertainment

entertainment

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Gilgo Beach: Police identify another victim in serial killing investigation

Apple is now the first public company to be valued at $3 trillion

Juul spent big to court Black leaders to promote its e

The high cost of giving birth even with insurance

Quicker fix for pulse oximeters urged during FDA public meeting

The cancer drug shortage isn’t new — and neither are the solutions

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Continuity nursing helped my family in our darkest PICU moments

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

hotspot

ARCH Venture Partners is raising $3 billion for a life sciences fund

Covid misinformation case heads to Supreme Court

Nearly two

Gilgo Beach: Police identify another victim in serial killing investigation

New Ultima Genomics DNA sequencer can read genome for $100

New Ultima Genomics DNA sequencer can read genome for $100

explore

knowledge

knowledge

focus